Private biopharmaceutical companies raised more than $1bn from venture capital, seed financing and government investments during the past week, including Eliem Therapeutics, Inc., which said on 24 May that it closed a $60m series B round just two months after it launched with $80m in VC funding.
Eliem’s $140m in combined financing during such a short span of time gives the company venture capital mega-round status at a time when many drug developers are raising $100m or...
Deals In Depth
For in-depth coverage of recent VC mega-rounds:
$125m In New Funding Nectar For Hummingbird As It Progresses Novel Antibodies